Download PDF
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(05): 496-500
DOI: 10.1055/s-0041-1736432
Case Report with Review of Literature

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rare Case Report with Literature Review

Authors

  • Nikita Oza‡   *

    1   Department of Histopathology, SRL Diagnostics – Centre of Excellence, Goregaon West, Mumbai, Maharashtra, India

  • Krishnakumar Rathnam‡   *

    2   Department of Medical Oncology, Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India

  • Gujral Sumeet

    3   Department of Pathology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India

  • Susan R. Honey 

    2   Department of Medical Oncology, Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India

  • S. V. Saju 

    2   Department of Medical Oncology, Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India

  • Kane Shubhada

    1   Department of Histopathology, SRL Diagnostics – Centre of Excellence, Goregaon West, Mumbai, Maharashtra, India
Further Information
Also available at
  Permissions and Reprints

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic neoplasm for which there are no effective therapies. We present a 70-year-old male patient with multiple reddish painless, nonpruritic, and nonpedunculated nodules over the trunk, forearm, and thighs for a duration of 3 months. The nodules measured 0.5 to 2 cm in diameter. The peripheral smear findings were within normal limits. Excision biopsy was performed. Histomorphology and immunohistochemistry (CD123, CD 56, CD4, HLA-DR, CD43, and CD68) confirmed the diagnosis of BPDCN. Findings of marrow aspiration, biopsy and imaging studies were within normal limits. Patient demonstrated a good response with complete disappearance of all nodules by initial 2 weeks of therapy with a modified Berlin–Frankfurt–Munster (BFM) acute lymphoblastic leukemia (ALL) protocol and has completed 8 doses (LSAP [lincosamides, streptogramins A and pleuromutilins chemotherapy], 5,000 units/m2). The patient tolerated protocol extremely well.

Keywords

blastic plasmacytoid dendritic cell neoplasm - chemotherapy - stem cell therapy - targeted therapy

Ethics Statement

The authors hereby declare that Institutional Ethics Committee did not mandate IEC review for this study. The collection of data from electronic medical record (EMR) and laboratory reports do not require an informed consent form as per the hospital's standard operating procedures.


* Authors have equally contributed for writing, review and editing the case report.




Publication History

Article published online:
05 December 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India